GRASPA® : Now in Phase II clinical trial for the treatment of recurrent Acute Lymphoblastic leukemia in adult and children (ALL).
GRASPA® is currently tested in other indications.
It consists in L-asparaginase encapsulated into red blood cells.
ERYtech Pharma received the agreement of the French Regulatory Affairs Agency and has started a Phase II clinical trial in the treatment of recurrent ALL in children and adults with GRASPA®.
ALL accounts for 80% of acute leukemias of childhood, with most cases occurring between ages 3 and 7. ALL also occurs in adults, where it accounts for 20% of all adult leukemias.
Launch animation only GRASPA 2008
Launch animation GRASPA 2008 full version
Go to the Cleav’ERY System®
